This report last month about the superbug has been quite concerning to all of us.
I want to talk about how we can incentivize development of new antibiotics.
We have been worried for quite some time here in Congress and at the agencies about the risk of resistant antibiotics.
We need a full panoply of investment in the research, the basic science, the drug discovery and drug development that la...
The goal of the biopharmaceutical accelerator will be in collaboration with our partners at NIAID.
opening statement
Medicare is stronger now after the Affordable Care Act.
the instability in the market is I don't think unexpected.
I worry that the bills that are under discussion today will actually increase costs and also harm access to insurance.
1.7 million Floridians now have been able to access affordable coverage.
myself and Congressman Bilirakis have introduced a bill that talks about lowering drug costs through competition.
For stepping back for too long, workers across our country have simply been putting in more and more hours without recei...
This legislation empowers regulators to make sure that rules, regulations and compliance requirements only apply to segm...
And what I am suggesting to you is that the breadth of this survey that you are giving undermines the constitutional req...
I love it when the VA always has somebody who's brand-new and who, you know, kind of washes their hands of the problem, ...
$44,000. And so are you going to try and get that money back? That's the question.
Chairman Coffman, Ranking Member Kuster, and Members of the Subcommittee, this concludes my prepared statement.
Are you disputing the factual nature of the OIG report in terms of the overpayment?
